LUCENTIS (ranibizumab) is not covered on the Reformulary. Reformulary covers BYOOVIZ, a biosimilar of LUCENTIS. BYOOVIZ is considered a preferred ranibizumab biosimilar as it offers the same clinical value at a lower net cost to the plan. BYOOVIZ requires Special Authorization.
Biosimilars are safe and clinically similar to the originator biologic, and have the potential to provide significant savings to you and your plan – this is essential to drug plan sustainability.
LUCENTIS is used
to treat various eye conditions, such as wet AMD